# A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

> **NCT07288138** · PHASE2 · RECRUITING · sponsor: **Eccogene** · enrollment: 160 (estimated)

## Conditions studied

- Metabolic Dysfunction-associated Steatohepatitis

## Interventions

- **DRUG:** Placebo
- **DRUG:** ECC4703
- **DRUG:** ECC0509
- **DRUG:** ECC4703

## Key facts

- **NCT ID:** NCT07288138
- **Lead sponsor:** Eccogene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-15
- **Primary completion:** 2027-09-15
- **Final completion:** 2027-09-29
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07288138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07288138, "A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07288138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*